Nov 06, 2025
Mounjaro (Tirzepatide): Evidence-Based Weight Management at Astute Clinic Malaysia
Introduction
Obesity and overweight are growing health concerns in Malaysia and worldwide, with far-reaching effects on metabolic health, cardiovascular function, and overall well-being. At Astute Clinic, we integrate advanced medical innovation with holistic wellness,
creating a refined and sustainable approach to body transformation.
One of the latest breakthroughs in medical weight management is tirzepatide (Mounjaro) — a once-weekly injectable medication that activates both GIP and GLP-1 receptors. Originally developed for type 2 diabetes, Mounjaro has demonstrated impressive outcomes for clinically significant weight reduction in multiple global studies.
Mechanism of Action & Clinical Rationale
Tirzepatide is a dual agonist of:
● Glucose-dependent insulinotropic polypeptide (GIP)
● Glucagon-like peptide-1 (GLP-1)
Together, these actions result in:
● Enhanced insulin sensitivity and improved glycaemic control
● Slowed gastric emptying and increased satiety (reduced caloric intake)
● Regulation of fat metabolism and energy expenditure
This dual-pathway synergy (GIP + GLP-1) provides a metabolic advantage over traditional GLP-1 agonists such as semaglutide (Ozempic), offering greater potential for fat-mass reduction and metabolic balance.
Key Clinical Evidence for Mounjaro (Tirzepatide)
1️⃣ SURMOUNT-2 Trial (Adults with overweight/obesity and type 2 diabetes):
Tirzepatide 15 mg achieved 15.7% mean weight loss at 72 weeks.
(HCPLive, 2023)
2️⃣ SURMOUNT-CN Trial (Non-diabetic adults in Asia):
Tirzepatide 10 mg and 15 mg led to −13.6% and −17.5% body-weight reduction
at 52 weeks, compared to −2.3% with placebo.
(JAMA Network, 2023)
3️⃣ SURPASS Programme (Post-hoc analysis):
Average 11.2 kg loss with tirzepatide 15 mg vs 6.9 kg with semaglutide 1 mg at 28 weeks.
(Eli Lilly Data, 2022)
4️⃣ Systematic Review & Meta-Analysis:
Across multiple studies, tirzepatide achieved significantly higher odds of ≥10%
weight loss than semaglutide (SMD = 0.75; 95% CI 0.52–0.92).
(PubMed, 2023)
Safety Considerations & Clinical Monitoring
Like all prescription weight-management therapies, tirzepatide must be administered
under medical supervision. Key considerations include:
● Safety profile: Similar to GLP-1 agonists — nausea, vomiting, constipation may
occur during dose escalation.
● Precautions: Contraindicated in patients with personal/family history of thyroid C-
cell tumours.
● Comprehensive monitoring: Regular review of metabolic markers (HbA1c, lipids,
thyroid, insulin resistance) and gradual dose adjustment ensure optimal response.
● Sustainability: Long-term results are maximised when combined with lifestyle,
nutritional and behavioural interventions.
Astute Clinic’s Weight-Management Blueprint with Mounjaro
At Astute Clinic, Mounjaro is positioned not as a “quick fix,” but as part of a medically
anchored transformation plan, integrating science, supervision, and aesthetics.
1. Baseline Assessment
Comprehensive evaluation including:
● Metabolic panel (HbA1c, lipids, thyroid, cortisol, insulin resistance)
● Lifestyle and nutritional profiling
2. Personalised Treatment Plan
● Weekly tirzepatide (as clinically indicated)
● Structured nutrition + guided resistance training
● Behavioural and sleep optimisation
3. Continuous Monitoring
● Weight and body-fat tracking every 8–12 weeks
● Side-effect management and dosage titration
● Integration with regenerative aesthetic care (skin tightening, toning support)
4. Maintenance Phase
● Transition after 6–12 months to sustainable lifestyle phase
● Optional tapering or adjunctive therapies
● Focus on muscle preservation, metabolic stability, and aesthetic proportion
Why Choose Astute Clinic
● Supervised by LCP-certified medical practitioners with expertise in metabolic and
regenerative medicine
● Located in DC Mall, Kuala Lumpur — offering discreet, premium care within a
fully equipped medical environment
● Integrated diagnostics + treatment + aesthetic maintenance under one roof
● Ethical, evidence-based approach — focusing on long-term health, not short-term
trends
Frequently Asked Questions (FAQ)
1. What is Mounjaro and how does it differ from Ozempic?
Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist, while Ozempic
(semaglutide) acts only on the GLP-1 receptor. This dual action helps improve insulin sensitivity, control appetite more effectively, and achieve greater fat loss in clinical trials.
2. Is Mounjaro suitable for non-diabetic patients?
Yes. While Mounjaro was initially approved for type 2 diabetes, multiple clinical trials (e.g., SURMOUNT-CN) have demonstrated significant weight loss in non-diabetic individuals with obesity or overweight when supervised by medical professionals.
3. How fast will I see results with Mounjaro?
Most patients experience noticeable weight reduction within 8–12 weeks, with optimal
results typically achieved after 6–12 months of continuous treatment combined with lifestyle changes and regular monitoring.
4. Are there any side effects?
Common side effects include nausea, reduced appetite, constipation, or fatigue, especially during the dose adjustment phase. These effects are usually temporary and
manageable under medical supervision.
5. Can I stop the injections once I reach my goal weight?
Clinical studies indicate that after discontinuing tirzepatide, patients may regain some
weight over the following year — but still maintain approximately 10% lower body
weight compared to their baseline. This shows that Mounjaro induces lasting metabolic benefits, but continued maintenance support (adjusted dosing, nutrition, exercise, and monitoring) is crucial to sustain results.
6. How does Astute Clinic ensure safety during treatment?
All treatments at Astute Clinic are physician-supervised, with comprehensive metabolic
screening and regular follow-ups. We prioritise patient safety, ethical prescribing, and
evidence-based practice.
Summary
Mounjaro (tirzepatide) represents a revolutionary step forward in evidence-based,
medically supervised weight management. When compared with Ozempic, clinical data consistently show greater efficacy and metabolic benefits. At Astute Clinic, we integrate this innovation into a holistic, physician- led programme designed for safety, sustainability, and aesthetic balance — ensuring that every transformation is guided by science and shaped with elegance.
